Recruiting
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
ClinicalTrials.gov IDNCT06441630
PhasePHASE3
Enrollment251
SponsorAddpharma Inc.
Age19 Years
SexALL
Conditions studied
Essential Hypertension
About this study
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Interventions
- Drug: AD-227A — Per Oral, 1 Tablet, Once a day for 8 weeks
- Drug: AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
- Drug: AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks
- Drug: Placebo of AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
- Drug: Placebo of AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks
Primary outcomes
- Change in MSSBP (Baseline to Week8)
Eligibility information
Inclusion Criteria:
* Signed informed consent
* Patients with Essential Hypertension
* Other inclusions applied
Exclusion Criteria:
* Patient with Secondary Hypertension
* Other exclusions applied
Study locations
- Gangnam CHA Medical Center, Seoul, South Korea
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.